ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

Neurelis, Inc. ("Company"), today announced a transaction with OrbiMed for the sale of the Company's rights, royalty ...

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand ...

ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS ...

Commercial launch of neffy®(epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by ...

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize neffy, the first and only needle-free emergency ...

We are convinced that neffy® will transform anaphylaxis, benefitting patients at risk and leading to a significant expansion of the market.” Exclusive rights to new indications ARS Pharma is ...

ARS Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing solutions for patients with allergic reactions, particularly anaphylaxis, through innovative products like their ...

In a pivotal development this year, the U.S. Food and Drug Administration approved neffy (epinephrine nasal spray) in August 2024 for emergency use in type 1 allergic reactions, such as anaphylaxis.

ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...

Exclusive license agreement with ALK-Abelló to commercialize neffy® in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal ...